NCT06678672 Contingency Management for Veteran Smokers Undergoing Major Elective Surgery
| NCT ID | NCT06678672 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Tobacco Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2025-08-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to design and test the first mobile contingency management (CM) smoking cessation intervention for military Veterans undergoing major elective surgery. Smoking is the leading risk factor for postoperative complications and is associated with longer hospital stays, reoperations, and 30-day mortality. Smoking rates among patients undergoing major elective surgery are high, 22.3-43.0%. It is imperative to identify efficacious, strategically timed smoking cessation interventions for surgery patients. CM incentivizes smoking cessation through positive reinforcement (rewards) when bioverified abstinence is achieved. To ensure feasibility, CM must be tailored to the clinical context. CM for smoking cessation has never been delivered before and after major surgery, nor has mobile CM bioverification been trialed perioperatively. The investigators will develop and test a tailored mobile smoking cessation CM protocol for Veterans undergoing major elective surgery.
Eligibility Criteria
Inclusion Criteria: * English-speaking; * Veteran enrolled in healthcare at SFVAHCS; * Veteran scheduled for major elective surgery within the next 6 months (including but not limited to: general, spinal, thoracic, vascular, urological, gynecological, orthopedic, gender affirming). Veterans, who are followed at SFVAHCS by Primary Care and are referred to outside institutions for major surgery (e.g., gynecological or gender-affirming surgeries) are also eligible to participate; * Current (past 30 days) cigarette smoking a minimum of 1 cigarette per day (average), assessed by Timeline Followback (TLFB); * Open to receiving smoking cessation interventions. Exclusion Criteria: Evaluated by investigative team medical record review and clinical assessment: - Psychotic disorders, bipolar disorder, neurocognitive disorder, or other psychiatric or medical conditions judged by the PI to be unstable based on medical record review and/or screening results; * Untreated, current, active problem gambling, assessed by medical record diagnosis and/ or Problem Gambling Severity Index (PGSI) score ≥ 8; * Enrollment in end of life/ palliative care; * Surgery with a clinical indication for cancer; * Unable to meet time commitment; * Currently pregnant or planning to become pregnant during the study (people of childbearing potential ages 18-55); * A suicide attempt or suicidal ideation with intent in the 30 days before enrollment; * Concurrent participation in another tobacco cessation trial.
Contact & Investigator
Ellen Herbst, MD
PRINCIPAL INVESTIGATOR
San Francisco VA Health Care System
Frequently Asked Questions
Who can join the NCT06678672 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Tobacco Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06678672 currently recruiting?
Yes, NCT06678672 is actively recruiting participants. Contact the research team at ellen.herbst@va.gov for enrollment information.
Where is the NCT06678672 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT06678672 clinical trial?
NCT06678672 is sponsored by University of California, San Francisco. The principal investigator is Ellen Herbst, MD at San Francisco VA Health Care System. The trial plans to enroll 36 participants.